EUROPE IMMUNOGLOBULIN MARKET FORECAST 2022-2030

 

TABLE OF CONTENTS

1.     RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES

1.2. SCOPE OF STUDY

1.3. METHODOLOGY

1.4. ASSUMPTIONS & LIMITATIONS

2.     EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES

2.2. MARKET OVERVIEW

3.     MARKET DYNAMICS

3.1. KEY DRIVERS

3.1.1. GROWTH IN GERIATRIC POPULATION

3.1.2. PREVALENCE OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS

3.1.3. INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES

3.2. KEY RESTRAINTS

3.2.1. HIGH COST OF THERAPY

3.2.2. HIGH RISK OF SIDE EFFECTS

4.     KEY ANALYTICS

4.1. IMPACT OF COVID-19 ON IMMUNOGLOBULIN MARKET

4.2. KEY MARKET TRENDS

4.3. PORTER’S FIVE FORCES ANALYSIS

4.3.1. BUYERS POWER

4.3.2. SUPPLIERS POWER

4.3.3. SUBSTITUTION

4.3.4. NEW ENTRANTS

4.3.5. INDUSTRY RIVALRY

4.4. OPPORTUNITY MATRIX

4.5. VENDOR LANDSCAPE

4.6. KEY BUYING CRITERIA

4.6.1. SOURCE

4.6.2. APPLICATION

4.6.3. EPITOPE

4.6.4. VALIDATION

5.     MARKET BY PRODUCT

5.1. IGG

5.2. IGA

5.3. IGM

5.4. IGE

5.5. IGD

6.     MARKET BY MODE OF DELIVERY

6.1. INTRAVENOUS IMMUNOGLOBULIN

6.2. SUBCUTANEOUS IMMUNOGLOBULIN

6.3. INTRAMUSCULAR IMMUNOGLOBULIN

7.     MARKET BY APPLICATION

7.1. HYPOGAMMA GLOBULINEMIA

7.2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

7.3. PRIMARY IMMUNODEFICIENCY DISEASES

7.4. MYASTHENIA GRAVIS

7.5. MULTIFOCAL MOTOR NEUROPATHY

7.6. IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

7.7. INFLAMMATORY MYOPATHIES

7.8. SPECIFIC ANTIBODY DEFICIENCY

7.9. GUILLAIN-BARRE SYNDROME

7.10. OTHER APPLICATIONS

8.     MARKET BY DISTRIBUTION CHANNEL

8.1. HOSPITAL PHARMACY

8.2. SPECIALTY PHARMACY

8.3. OTHER DISTRIBUTION CHANNELS

9.     MARKET BY END-USER

9.1. HOSPITALS & CLINICS

9.2. HOMECARE

10. GEOGRAPHICAL ANALYSIS

10.1. EUROPE

10.1.1. MARKET SIZE & ESTIMATES

10.1.2. KEY GROWTH ENABLERS

10.1.3. KEY CHALLENGES

10.1.4. KEY PLAYERS

10.1.5. COUNTRY ANALYSIS

10.1.5.1.    UNITED KINGDOM

10.1.5.2.    GERMANY

10.1.5.3.    FRANCE

10.1.5.4.    SPAIN

10.1.5.5.    ITALY

10.1.5.6.    NORDIC COUNTRIES

10.1.5.7.    REST OF EUROPE

11. COMPETITIVE LANDSCAPE

11.1. KEY STRATEGIC DEVELOPMENTS

11.1.1. MERGERS & ACQUISITIONS

11.1.2. PRODUCT LAUNCHES & DEVELOPMENTS

11.1.3. PARTNERSHIPS & AGREEMENTS

11.1.4. BUSINESS EXPANSIONS & DIVESTITURES

11.2. COMPANY PROFILES

11.2.1. ADMA BIOLOGICS

11.2.2. BIO PRODUCTS LABORATORY

11.2.3. BIOTEST AG

11.2.4. CHINA BIOLOGIC PRODUCTS INC

11.2.5. CSL BEHRING

11.2.6. GRIFOLS SA

11.2.7. KAMADA LTD

11.2.8. KEDRION BIOPHARMA

11.2.9. LFB GROUP

11.2.10. OCTAPHARMA AG

11.2.11. PFIZER INC

11.2.12. SANQUIN PLASMA PRODUCTS BV

11.2.13. SHANGHAI RAAS BLOOD PRODUCTS CO LTD

11.2.14. SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD

11.2.15. TAKEDA PHARMACEUTICAL COMPANY LIMITED

 

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - IMMUNOGLOBULIN

TABLE 2: EUROPE IMMUNOGLOBULIN MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 3: EUROPE IMMUNOGLOBULIN MARKET, BY PRODUCT, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 4: EUROPE IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 5: EUROPE IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 6: EUROPE IMMUNOGLOBULIN MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 7: EUROPE IMMUNOGLOBULIN MARKET, BY APPLICATION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 8: EUROPE IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 9: EUROPE IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 10: EUROPE IMMUNOGLOBULIN MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 11: EUROPE IMMUNOGLOBULIN MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 12: EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 13: EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 14: LEADING PLAYERS OPERATING IN EUROPE IMMUNOGLOBULIN MARKET

TABLE 15: LIST OF MERGERS & ACQUISITIONS

TABLE 16: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 17: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 18: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

 

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: OPPORTUNITY MATRIX

FIGURE 4: VENDOR LANDSCAPE

FIGURE 5: KEY BUYING CRITERIA

FIGURE 6: EUROPE IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2021

FIGURE 7: EUROPE IMMUNOGLOBULIN MARKET, BY IGG, 2022-2030 (IN $ MILLION)

FIGURE 8: EUROPE IMMUNOGLOBULIN MARKET, BY IGA, 2022-2030 (IN $ MILLION)

FIGURE 9: EUROPE IMMUNOGLOBULIN MARKET, BY IGM, 2022-2030 (IN $ MILLION)

FIGURE 10: EUROPE IMMUNOGLOBULIN MARKET, BY IGE, 2022-2030 (IN $ MILLION)

FIGURE 11: EUROPE IMMUNOGLOBULIN MARKET, BY IGD, 2022-2030 (IN $ MILLION)

FIGURE 12: EUROPE IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY MODE OF DELIVERY, IN 2021

FIGURE 13: EUROPE IMMUNOGLOBULIN MARKET, BY INTRAVENOUS IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)

FIGURE 14: EUROPE IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)

FIGURE 15: EUROPE IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)

FIGURE 16: EUROPE IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2021

FIGURE 17: EUROPE IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2030 (IN $ MILLION)

FIGURE 18: EUROPE IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, 2022-2030 (IN $ MILLION)

FIGURE 19: EUROPE IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2030 (IN $ MILLION)

FIGURE 20: EUROPE IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2030 (IN $ MILLION)

FIGURE 21: EUROPE IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2030 (IN $ MILLION)

FIGURE 22: EUROPE IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2030 (IN $ MILLION)

FIGURE 23: EUROPE IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2030 (IN $ MILLION)

FIGURE 24: EUROPE IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2030 (IN $ MILLION)

FIGURE 25: EUROPE IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2030 (IN $ MILLION)

FIGURE 26: EUROPE IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2030 (IN $ MILLION)

FIGURE 27: EUROPE IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2021

FIGURE 28: EUROPE IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2030 (IN $ MILLION)

FIGURE 29: EUROPE IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2030 (IN $ MILLION)

FIGURE 30: EUROPE IMMUNOGLOBULIN MARKET, BY OTHER DISTRIBUTION CHANNELS, 2022-2030 (IN $ MILLION)

FIGURE 31: EUROPE IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021

FIGURE 32: EUROPE IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2030 (IN $ MILLION)

FIGURE 33: EUROPE IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2030 (IN $ MILLION)

FIGURE 34: EUROPE IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 35: UNITED KINGDOM IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 36: GERMANY IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 37: FRANCE IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 38: SPAIN IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 39: ITALY IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 40: NORDIC COUNTRIES IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 41: REST OF EUROPE IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

 

KEY FINDINGS

The Europe immunoglobulin market is predicted to progress with a CAGR of 6.90% across the forecast period of 2022 to 2030. The regional market’s growth is fuelled by supportive government initiatives for immunoglobulin and plasma donation, the prevalence of different immunodeficiency diseases, and the growth of the biotechnology industry.

 

Get more Insights into the Europe Immunoglobulin Market:

https://inkwoodresearch.com/reports/europe-immunoglobulin-market/

 

MARKET INSIGHTS

The Europe immunoglobulin market growth evaluation entails the study of the United Kingdom, Italy, Nordic Countries, France, Germany, Spain, and Rest of Europe. The increasing investments by key players as well as industry giants, primarily for vaccine development and research, is one of the major drivers anticipated to strengthen the growth of the immunoglobulin market in France during the forecast years. In this regard, Pfizer announced its plans to include a production facility for an antiviral COVID-19 drug in the country in 2022. It also entails an investment of $594 million in France over the period of the next five years. Similarly, in 2020, AstraZeneca announced an investment of $520 million in the country within the spectrum of manufacturing, research, and development.

On the other hand, in 2019, Spain-based Grifols announced the approval from the United States Food and Drug Administration (FDA) for Xembify®, the company’s first 20% subcutaneous immunoglobulin for treating primary immunodeficiencies. The product represents a substantial research and development milestone for Grifols, as well as a critical step for its long-term sustainable growth strategy. Therefore, the abovementioned factors are estimated to propel the Europe immunoglobulin market growth over the forecast years.

 

COMPETITIVE INSIGHTS

The top companies operating in the market include LFB Group, Biotest AG, Grifols SA, etc.

 

Our report offerings include:

·       Explore key findings of the overall market

·       Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)

·       Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions

·       Market Segmentation cater to a thorough assessment of key segments with their market estimations

·       Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share

·       Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.

·       Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.

·       Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

 

SEGMENTATION

1.     ADMA BIOLOGICS

2.     BIO PRODUCTS LABORATORY

3.     BIOTEST AG

4.     CHINA BIOLOGIC PRODUCTS INC

5.     CSL BEHRING

6.     GRIFOLS SA

7.     KAMADA LTD

8.     KEDRION BIOPHARMA

9.     LFB GROUP

10. OCTAPHARMA AG

11. PFIZER INC

12. SANQUIN PLASMA PRODUCTS BV

13. SHANGHAI RAAS BLOOD PRODUCTS CO LTD

14. SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD

15. TAKEDA PHARMACEUTICAL COMPANY LIMITED